A recombinant pseudorabies virus expressing rabies virus glycoprotein: Safety and immunogenicity in dogs

作者：Yuan Ziguo; Zhang Shoufeng; Liu Ye; Zhang Fei; Fooks Anthony R; Li Qianxue; Hu Rongliang^*

来源：Vaccine, 2008, 26(10): 1314-1321.

DOI：10.1016/j.vaccine.2007.12.050

• recombinant pseudorabies virus
• rabies virus gtycoprotein
• oral vaccination
• dogs

Several recombinant vaccines expressing the rabies virus glycoprotein have been developed, particularly for the oral vaccination of wildlife. White these vaccines induce protective immunity in some animal species such as foxes, they are less effective in others. Pseudorabies virus (PRV) has been licensed for use as a live vaccine in pigs and possesses an excellent safety and efficacy record. We have used it to construct a recombinant virus, rPRV/eGFP/rgp, expressing the rabies virus glycoprotein. This recombinant virus has been shown to be safe for dogs by oral and intramuscular routes of inoculation and was demonstrated to induce immune responses against both pseudorabies and rabies in dogs after a single oral dose of 2 x 10(7.0) plaque forming units (PFU). Neutralizing antibody titers against rabies reached >0.5 IU/ml and 1:64-1:128 against pseudorabies by 5 weeks post -vaccination in all dogs, indicating that the pseudorabies virus vector infected dogs and replicated in vivo, and that the rabies virus glycoprotein had been expressed and an effective immune response elicited. Antibody titers were maintained for over 6 months. This suggests that pseudorabies virus could be an effective live vector for recombinant rabies oral vaccination.

• 出版日期2008-3-4
• 单位吉林大学; 中国人民解放军军事医学科学院